Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin (Q44993935)

8 December 2017

title

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin (English)

1 reference

8 December 2017

1 reference

1 reference

Paloma Muñoz de Rueda

1

1 reference

8 December 2017

Miguel-Ángel López-Nevot

2

1 reference

8 December 2017

Pablo Sáenz-López

3

1 reference

8 December 2017

Jorge Casado

4

1 reference

8 December 2017

Antonia Martín-Casares

5

1 reference

8 December 2017

Pablo Palomares

6

1 reference

8 December 2017

Rosa Quiles

7

1 reference

8 December 2017

Ana Gila

8

1 reference

8 December 2017

Manuel Romero-Gómez

9

1 reference

8 December 2017

Esther-José Pavón

10

1 reference

8 December 2017

José-Antonio Muñoz

11

1 reference

8 December 2017

Angel Carazo

12

1 reference

8 December 2017

Paloma Sanz-Cameno

13

1 reference

8 December 2017

Ricardo Moreno-Otero

14

1 reference

8 December 2017

Moisés Diago

15

1 reference

8 December 2017

Josefa León

16

1 reference

8 December 2017

Angeles Ruiz-Extremera

17

1 reference

8 December 2017

Javier Salmerón

18

1 reference

8 December 2017

language of work or name

English

0 references

publication date

14 June 2011

1 reference

The American Journal of Gastroenterology

8 December 2017

published in

1 reference

8 December 2017

volume

106

1 reference

8 December 2017

issue

7

1 reference

8 December 2017

page(s)

1246-1254

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

8 December 2017

1 reference

Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of Hepatitis C Virus Genotype 1 and Their Relationships to Pegylated Interferon-Ribavirin Treatment Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Treatment predictors of a sustained virologic response in hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Restriction fragment length polymorphism of adhesin gene hpaA from different Helicobacter pylori strains of Chongqing, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

A comparative review of HLA associations with hepatitis B and C viral infections across global populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Host genetic determinants in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Polymorphism in the Human Major Histocompatibility Complex and Early Viral Decline during Treatment of Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Human interferon-lambda3 is a potent member of the type III interferon family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

Inhibition of dynamin-dependent endocytosis interferes with type III IFN expression in bacteria-infected human monocyte-derived DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.82

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.82

1 reference

Dimensions Publication ID

8 December 2017

1018729176

0 references

1 reference